In vitiligo, cutaneous depigmentation is accompanied by increased T cell cytolytic activity targeting melanocytes, indicating that autoimmune tolerance is disrupted.
| INTRODUCTION
Vitiligo is a chronic skin disease with a worldwide incidence rate of approximately 0.5%-1.0%. 1 The loss of melanocytes in the epidermis is the key process in the development of vitiligo, which is the direct reason for the formation of patchy depigmentation on the skin of vitiligo patients. Recent studies have demonstrated that overactive T-lymphocytes mediate the destruction of melanocytes in the pathogenesis of vitiligo, 2, 3 indicating that autoimmune tolerance is disrupted in the disease. was further supported by many other subsequent researches. 5, 6 Moreover, increasing the abundance of Tregs by CCL22 overexpression can reduce depigmentation in two mouse models of vitiligo, 7 indicating that replenishing Tregs can repair the disrupted autoimmune tolerance and is a promising treatment for vitiligo.
Recently, it is reported that Tregs are suppressed in vitiligo not only on their amounts but also on their function. The polymorphisms of several immunosuppressive genes expressed in Tregs including transcription factor Forkhead box P3 (Foxp3), 8 interleukin-10 (IL-10) 9 and transforming growth factor b (TGF-b) 10 are associated with susceptibility to vitiligo. Moreover, the function of Tregs has been shown impaired in vitiligo patients, with weaker suppressive effect of Tregs on autologous CD8 + T cells 4 and decreased expression level of Foxp3 and cytotoxic T lymphocyte antigen-4 (CTLA-4) that induces the anergy of effector T cells. 6 Therefore, amending the impaired function of Tregs is another way to reconstruct the autoimmune tolerance and may be applied to the treatment for vitiligo. 
| Regulatory activity assay
To test the regulatory activity of Tregs, 3. 
| Proliferation assays in vitro
To 
| Elisa assay for serum cytokines
The serum levels of anti-inflammatory cytokines including TGF-b, IL-10 and sCTLA-4 were measured by Elisa kits (Xi Tang Biotechnology, Shanghai, China) according to the manufacturer's instructions. The serum level of HO-1 and its reactive products, bilirubin, CoHb and iron (Fe 2+ ) were also tested by the corresponding serum detection kits (Xi Tang Biotechnology, Shanghai, China) according to the manufacturer's instructions.
| Hemin treatment
To assess the effect of Hemin, a HO-1 inducer, on Treg cell function, Tregs were isolated from patients or controls and cultured in RPMI 1640 in the presence of Hemin at a concentration of 10 lmol/L for 24 hours. Tregs were then washed with PBS, and the proliferation of Tregs was detected by flow cytometry as described previously. The co-culture system of CD8 + T cells and Hemin-treated Tregs was established, and the reduction in CD8 + T cell proliferation rate was detected to evaluate the inhibitory capacity of Hemintreated Tregs.
| Statistics
Data were presented as mean AE SD throughout the manuscript and analysed for statistical significance of differences between groups using Student's t test accounting to unequal variance. healthy controls or stable patients, whereas there was no significant difference between healthy controls and stable patients (Figure 1C) . We also compared the percentage of Tregs in patients with different lesional areas, however, with no significant difference observed ( Figure 1D ). Therefore, the amount of Tregs can be decreased in active vitiligo patients, rather than in stable vitiligo patients.
| The immunoregulatory function and proliferative ability of Tregs were suppressed in vitiligo patients
The homoeostasis of the immune system depends on proper function of Treg cells. We compared the suppressive ability of Tregs towards CD8 + effector T cells. It turned out that the proliferation rate of effector T cells decreased more than 10% with the co-culture of Tregs isolated from healthy controls, but only reduced less than 5% with the co-culture of Tregs from vitiligo patients (Figure 2A,B) . Figure 4A,B) . In summary, our study demonstrated that HO-1 is responsible for the impaired function of regulatory T cells in vitiligo patients.
Although further studies are warranted to determine the involved mechanisms in more details, HO-1 is of great potential to be used as a novel therapeutic target, offering a promising alternative to our current approaches to managing vitiligo. Values are presented as the mean AE SD, *P < .05, ***P < .001. HC, healthy controls; VP, vitiligo patients
